Transcode Therapeutics Secures Up to $14 Million Standby Equity Purchase Agreement with Yorkville

Transcode Therapeutics, Inc. (RNAZ) announced it has entered into a Standby Equity Purchase Agreement (SEPA) with YA II PN, LTD (Yorkville), providing the company with the option to sell up to $14 million of its common stock. This agreement offers RNAZ financial flexibility, allowing it to access capital at its discretion to support ongoing operations and development initiatives without an immediate obligation to sell shares. The pricing for any future advances will be set at 97% of the lowest daily volume weighted average price (VWAP) over a three-day period, with the company retaining the option to establish a minimum price. This facility provides a potential funding source for the emerging growth company, subject to certain conditions including a resale registration statement.